Beranda › Karsinoma Neuroendokrin
Uji klinis Karsinoma Neuroendokrin yang merekrut di AS
16 studi untuk Karsinoma Neuroendokrin merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX6 studi
- New York City, NY6 studi
- Arlington, VA5 studi
- Dallas, TX4 studi
- Los Angeles, CA4 studi
- Washington, DC4 studi
- New Haven, CT3 studi
- Seattle, WA3 studi
- Columbus, OH3 studi
- Atlanta, GA3 studi
- Nashville, TN3 studi
- Grand Rapids, MI3 studi
- Denver, CO3 studi
- St. Louis, MO3 studi
Berdasarkan negara bagian
- California6 studi
- Colorado4 studi
- Connecticut3 studi
- Florida5 studi
- Georgia4 studi
- Louisiana3 studi
- Maryland6 studi
- Michigan3 studi
- Missouri3 studi
- New Jersey4 studi
- New York6 studi
- Ohio4 studi
- Tennessee4 studi
- Texas8 studi
- Virginia5 studi
- Washington4 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Menerima pesertaFase 2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06406465Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07509034Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05237934Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07278479Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07080242A Study of Armored CAR T Cells in People With Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07783477A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT05652686Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Menerima pesertaFase 1/2
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05000294A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07174583A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT06041516A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Apr 2026 · NCT06889493A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT06943521Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.